BIOGEN INC (BIIB) Stock Fundamental Analysis
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
142.5 USD
-1.31 (-0.91%)
142.2 USD
-0.3 (-0.21%)
We assign a fundamental rating of 5 out of 10 to BIIB. BIIB was compared to 540 industry peers in the Biotechnology industry. BIIB scores excellent on profitability, but there are some minor concerns on its financial health. BIIB is valued quite cheap, but it does not seem to be growing. With these ratings, BIIB could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year BIIB was profitable.
BIIB had a positive operating cash flow in the past year.
Each year in the past 5 years BIIB has been profitable.
BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIIB has a Return On Assets of 5.40%. This is amongst the best in the industry. BIIB outperforms 91.48% of its industry peers.
BIIB has a Return On Equity of 8.68%. This is amongst the best in the industry. BIIB outperforms 92.59% of its industry peers.
BIIB has a better Return On Invested Capital (9.52%) than 94.07% of its industry peers.
BIIB had an Average Return On Invested Capital over the past 3 years of 10.57%. This is significantly below the industry average of 15.95%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
BIIB's Profit Margin of 15.31% is amongst the best of the industry. BIIB outperforms 93.70% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
BIIB has a better Operating Margin (27.35%) than 96.30% of its industry peers.
In the last couple of years the Operating Margin of BIIB has declined.
With an excellent Gross Margin value of 75.43%, BIIB belongs to the best of the industry, outperforming 82.96% of the companies in the same industry.
In the last couple of years the Gross Margin of BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
Compared to 5 years ago, BIIB has less shares outstanding
The debt/assets ratio for BIIB has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.05 indicates that BIIB is not in any danger for bankruptcy at the moment.
BIIB has a Altman-Z score of 3.05. This is in the better half of the industry: BIIB outperforms 70.56% of its industry peers.
BIIB has a debt to FCF ratio of 3.40. This is a good value and a sign of high solvency as BIIB would need 3.40 years to pay back of all of its debts.
The Debt to FCF ratio of BIIB (3.40) is better than 93.89% of its industry peers.
BIIB has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.36, BIIB is doing worse than 70.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 3.05 |
ROIC/WACC1.03
WACC9.25%
2.3 Liquidity
A Current Ratio of 2.50 indicates that BIIB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.50, BIIB is doing worse than 69.07% of the companies in the same industry.
A Quick Ratio of 1.79 indicates that BIIB should not have too much problems paying its short term obligations.
BIIB has a worse Quick ratio (1.79) than 76.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
The earnings per share for BIIB have decreased by -3.61% in the last year.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
The Revenue has been growing slightly by 3.36% in the past year.
BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
3.2 Future
Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 1.26% on average per year.
BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.33% yearly.
EPS Next Y-1.7%
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
EPS Next 5Y1.26%
Revenue Next Year0.4%
Revenue Next 2Y-1.84%
Revenue Next 3Y-1.15%
Revenue Next 5Y-0.33%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BIIB is valuated reasonably with a Price/Earnings ratio of 8.90.
BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.22% of the companies in the same industry.
When comparing the Price/Earnings ratio of BIIB to the average of the S&P500 Index (27.38), we can say BIIB is valued rather cheaply.
BIIB is valuated reasonably with a Price/Forward Earnings ratio of 8.84.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.59% of the companies listed in the same industry.
BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.9 | ||
| Fwd PE | 8.84 |
4.2 Price Multiples
BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.59% of the companies in the same industry.
97.78% of the companies in the same industry are more expensive than BIIB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.31 | ||
| EV/EBITDA | 7.08 |
4.3 Compensation for Growth
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
142.5
-1.31 (-0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.67%
Inst Owner Change-0.33%
Ins Owners0.14%
Ins Owner Change3.35%
Market Cap20.89B
Analysts72.86
Price Target172.46 (21.02%)
Short Float %3.23%
Short Ratio3.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)-0.23%
PT rev (3m)-0.51%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)-3.55%
EPS NY rev (1m)6.04%
EPS NY rev (3m)5.87%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)2.72%
Revenue NY rev (1m)4.46%
Revenue NY rev (3m)4.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.9 | ||
| Fwd PE | 8.84 | ||
| P/S | 2.09 | ||
| P/FCF | 11.31 | ||
| P/OCF | 9.87 | ||
| P/B | 1.18 | ||
| P/tB | 12.48 | ||
| EV/EBITDA | 7.08 |
EPS(TTM)16.01
EY11.24%
EPS(NY)16.12
Fwd EY11.31%
FCF(TTM)12.6
FCFY8.84%
OCF(TTM)14.44
OCFY10.13%
SpS68.19
BVpS120.28
TBVpS11.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 3.05 |
F-Score6
WACC9.25%
ROIC/WACC1.03
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-1.7%
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
EPS Next 5Y1.26%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.4%
Revenue Next 2Y-1.84%
Revenue Next 3Y-1.15%
Revenue Next 5Y-0.33%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year9.29%
EBIT Next 3Y4.38%
EBIT Next 5Y5.37%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%